Germany’s e-health transformation makes uneven progress
Posted:
Germany’s e-health transformation makes uneven progress. This McKinsey & Company article summarizes the findings from the annual book "eHealth Monitor" that was published recently in the MWV Publishing House.
Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But, the Food and Drug Administration approved Kisqali in combination with hormone therapy for patients with certain early-stage breast cancers. …
Wearable technology that monitors our bodies can be helpful and harmful.
Wearable technology affords the opportunity to check, re-check, and check again, leading to fixation.
Read the full article in the Psychology Today blog post here.